Cerus Corporation (Nasdaq:CERS) today announced that the National Institute of Allergy and Infectious Disease, a division of the National Institutes of Health, has awarded the company $3.8 million to develop an anthrax vaccine with greater potency than currently available vaccines. The grant will be awarded over a three-year period, and Cerus will receive approximately $1.4 million for the first year of development.
